252 related articles for article (PubMed ID: 36438489)
1. N6-methyladenosine-associated prognostic pseudogenes contribute to predicting immunotherapy benefits and therapeutic agents in head and neck squamous cell carcinoma.
Tan L; Qin Y; Xie R; Xia T; Duan X; Peng L; You R; Liu Y; Zou X; Zhang M; Lin M; Chen M
Theranostics; 2022; 12(17):7267-7288. PubMed ID: 36438489
[No Abstract] [Full Text] [Related]
2. RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic metastasis and epithelial-mesenchymal transition of head and neck squamous carcinoma cells via stabilizing slug mRNA in an m6A-dependent manner.
Yu D; Pan M; Li Y; Lu T; Wang Z; Liu C; Hu G
J Exp Clin Cancer Res; 2022 Jan; 41(1):6. PubMed ID: 34980207
[TBL] [Abstract][Full Text] [Related]
3. A Signature of N
Chen J; Lu T; Zhong F; Lv Q; Fang M; Tu Z; Ji Y; Li J; Gong X
Front Immunol; 2022; 13():809872. PubMed ID: 35185897
[TBL] [Abstract][Full Text] [Related]
4. Construction and clinical evaluation of N6-methyladenosine risk signature of YTHDC2, IGF2BP2, and HNRNPC in head and neck squamous cell carcinoma.
Yue Q; Xu L; Zhang D
Hua Xi Kou Qiang Yi Xue Za Zhi; 2022 Dec; 40(6):704-709. PubMed ID: 36416324
[TBL] [Abstract][Full Text] [Related]
5. Integrated Genomic and Functional microRNA Analysis Identifies miR-30-5p as a Tumor Suppressor and Potential Therapeutic Nanomedicine in Head and Neck Cancer.
Saleh AD; Cheng H; Martin SE; Si H; Ormanoglu P; Carlson S; Clavijo PE; Yang X; Das R; Cornelius S; Couper J; Chepeha D; Danilova L; Harris TM; Prystowsky MB; Childs GJ; Smith RV; Robertson AG; Jones SJM; Cherniack AD; Kim SS; Rait A; Pirollo KF; Chang EH; Chen Z; Van Waes C
Clin Cancer Res; 2019 May; 25(9):2860-2873. PubMed ID: 30723145
[TBL] [Abstract][Full Text] [Related]
6. A Metabolism-Related Gene Prognostic Index Bridging Metabolic Signatures and Antitumor Immune Cycling in Head and Neck Squamous Cell Carcinoma.
Du K; Zou J; Wang B; Liu C; Khan M; Xie T; Huang X; Shen P; Tian Y; Yuan Y
Front Immunol; 2022; 13():857934. PubMed ID: 35844514
[TBL] [Abstract][Full Text] [Related]
7. Application of Machine Learning in Developing a Novelty Five-Pseudogene Signature to Predict Prognosis of Head and Neck Squamous Cell Carcinoma: A New Aspect of "Junk Genes" in Biomedical Practice.
Xing L; Zhang X; Guo M; Zhang X; Liu F
DNA Cell Biol; 2020 Apr; 39(4):709-723. PubMed ID: 32045271
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and chemotherapeutic implications of a novel four-gene pyroptosis model in head and neck squamous cell carcinoma.
Yuan P; Jiang S; Wang Q; Wu Y; Jiang Y; Xu H; Jiang L; Luo X
PeerJ; 2024; 12():e17296. PubMed ID: 38756442
[TBL] [Abstract][Full Text] [Related]
9.
Chen L; Lin J; Lan B; Xiong J; Wen Y; Chen Y; Chen CB
Comput Math Methods Med; 2022; 2022():5851755. PubMed ID: 36510584
[TBL] [Abstract][Full Text] [Related]
10. Construction of an m6A-related lncRNA pair prognostic signature and prediction of the immune landscape in head and neck squamous cell carcinoma.
Zhou C; Wang S; Shen Z; Shen Y; Li Q; Shen Y; Huang J; Deng H; Ye D; Zhan G; Li J
J Clin Lab Anal; 2022 Jan; 36(1):e24113. PubMed ID: 34783061
[TBL] [Abstract][Full Text] [Related]
11. Establishment and validation of immune microenvironmental gene signatures for predicting prognosis in patients with head and neck squamous cell carcinoma.
Wang J; Tian Y; Zhu G; Li Z; Wu Z; Wei G; Zhuang L; Li Z; Chen X; Zhang X; Zheng J; Cai G
Int Immunopharmacol; 2021 Aug; 97():107817. PubMed ID: 34091115
[TBL] [Abstract][Full Text] [Related]
12. RNA N6-methyladenosine (m6A) modification in HNSCC: molecular mechanism and therapeutic potential.
Sun X; Fu S; Yuan X; Pu X; Wang R; Wang X; Lu H
Cancer Gene Ther; 2023 Sep; 30(9):1209-1214. PubMed ID: 37221404
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive bioinformatics analysis and experimental validation: An anoikis-related gene prognostic model for targeted drug development in head and neck squamous cell carcinoma.
Qiu L; Tao A; Sun X; Liu F; Ge X; Li C
Oncol Res; 2023; 31(5):715-752. PubMed ID: 37547764
[TBL] [Abstract][Full Text] [Related]
14. AVPR2 is a potential prognostic biomarker and correlated with immune infiltration in head and neck squamous cell carcinoma.
Mao L; Pan Z; Chen W; Hu W; Chen X; Dai H
BMC Med Genomics; 2023 Mar; 16(1):67. PubMed ID: 36998036
[TBL] [Abstract][Full Text] [Related]
15. Integrated analysis of deregulation microRNA expression in head and neck squamous cell carcinoma.
Qi CL; Sheng JF; Huang ML; Zou Y; Wang YP; Wang F; Zeng F; Hua QQ; Chen SM
Medicine (Baltimore); 2021 Feb; 100(6):e24618. PubMed ID: 33578572
[TBL] [Abstract][Full Text] [Related]
16. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.
Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X
Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553
[TBL] [Abstract][Full Text] [Related]
17. miR-34a-5p functions as a tumor suppressor in head and neck squamous cell cancer progression by targeting Flotillin-2.
Li X; Zhao S; Fu Y; Zhang P; Zhang Z; Cheng J; Liu L; Jiang H
Int J Biol Sci; 2021; 17(15):4327-4339. PubMed ID: 34803501
[TBL] [Abstract][Full Text] [Related]
18. Aberrations of m6A regulators are associated with tumorigenesis and metastasis in head and neck squamous cell carcinoma.
Arumugam P; George R; Jayaseelan VP
Arch Oral Biol; 2021 Feb; 122():105030. PubMed ID: 33383437
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of immune cell infiltration and significant genes in head and neck squamous cell carcinoma.
Zhang S; Zhang W; Zhang J
Oral Oncol; 2022 Mar; 126():105755. PubMed ID: 35144208
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive investigation into the influence of glycosylation on head and neck squamous cell carcinoma and development of a prognostic model for risk assessment and anticipating immunotherapy.
Ma H; Xiong L; Zhao B; Hahan Z; Wei M; Shi H; Yang S; Ren Q
Front Immunol; 2024; 15():1364082. PubMed ID: 38562924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
